The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age
- 26 May 2010
- journal article
- clinical trial
- Published by Taylor & Francis Ltd in Gynecological Endocrinology
- Vol. 27 (4), 216-224
- https://doi.org/10.3109/09513590.2010.487595
Abstract
To investigate the effect of oral contraceptives (OC), metformin and ovulation induction with gonadotropins on circulating anti-müllerian hormone (AMH). Prospective clinical study. Thirty patients with PCOS (Group 1), 15 normogonadotropic anovulatory infertile women (WHO 2) (Group 2) and 15 normoovulatory control women (Group 3). Patients in Group 1 received OC (n = 12), metformin (n = 11) or no-treatment (n = 7) for 6 months. Ovulation induction with FSH or hMG was used in Group 2. Total follicle number (TFN) and hormonal (fasting insulin and glucose, testosterone, SHBG, LH, androstenedione and AMH) measurements at baseline and during therapy. Basal AMH and TFN were higher in Groups 1 and 2 than in controls. Only TFN was significantly related to AMH level in Groups 1 and 2. AMH level was significantly reduced during OC treatment, and there was a trend for AMH decrease during metformin therapy. No significant changes in AMH level were observed during ovulation induction. TFN was the only parameter showing a significant positive correlation with circulating AMH over the 6-month treatment period in patients in Group 2. AMH is an accurate marker of the antral follicle pool in WHO-2/PCOS women but the measurement of AMH is not likely to be helpful in the management of those patients.Keywords
This publication has 27 references indexed in Scilit:
- Anti-Müllerian hormone and ovarian dysfunctionTrends in Endocrinology & Metabolism, 2008
- Follicle dynamics and anovulation in polycystic ovary syndromeHuman Reproduction Update, 2008
- Anti-Müllerian Hormone: Cinderella Finds New AdmirersJournal of Clinical Endocrinology & Metabolism, 2006
- PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO‐II anovulation and association with metabolic factorsBJOG: An International Journal of Obstetrics and Gynaecology, 2006
- Anti-Müllerian hormone: a new marker for ovarian functionReproduction, 2006
- Basal and stimulation day 5 anti-Müllerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist–gonadotropin treatmentHuman Reproduction, 2005
- The importance of diagnostic criteria in the association between the metabolic syndrome and cardiovascular disease in obese subjectsInternational Journal of Obesity, 2005
- Anti-Müllerian Hormone Serum Concentrations in Normoovulatory and Anovulatory Women of Reproductive AgeJournal of Clinical Endocrinology & Metabolism, 2004
- Elevated Serum Level of Anti-Mullerian Hormone in Patients with Polycystic Ovary Syndrome: Relationship to the Ovarian Follicle Excess and to the Follicular ArrestJournal of Clinical Endocrinology & Metabolism, 2003
- Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimensHuman Reproduction, 2001